Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Lung Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Lung Cancer
    Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
    NICE Issues Final Guidance on the Use of Erlotinib for the Treatment of NSCLC - (DGNews)
    TopAbstracts in Lung Cancer 11/26/2008 - (DGNews)
    Oral Gefitinib as Effective as Injected Docetaxel for Survival of Patients With NSCLC - (DGNews)
    TopAbstracts in Lung Cancer 11/12/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Lung Cancer
    • Latest Data From Chicago Provide New Insight Into the Evolving Role of Cytotoxic and Targeted Therapies in Early-Stage NSCLC
    • Alpha1-Antitrypsin Deficiency: Incidence, Screening, and Management
    • Early Detection of Alpha1-Antitrypsin (AAT) Deficiency Helps Prevent Disease Progression
    • What Is the Best Approach to Treating Alpha1-Antitrypsin (AAT) Deficiency?
    • Silica-Related Lung Disease: It's Still Here

      Webcasts/CME archive

       Recent cases - Lung Cancer
        A Resected Case of Solitary Pancreatic Metastasis from Adenocarcinoma of the Lung
        Diverse Histologic Appearances in Pulmonary Mucinous Cystic Neoplasia: A Case Report
        Extrapulmonary Small Cell Sarcinoma: Involvement of the Brain Without Evidence of Extracranial Malignancy by Serial PET/CT Scans
        Neurocognitive Deficits in a Patient with Small Cell Lung Cancer: A Case Report
        Hypertrophic Pulmonary Osteoarthropathy Secondary to Bronchial Adenocarcinoma and Coexisting Pulmonary Tuberculosis: A Case Report

        Cases archive
          




        my personal edition > lung cancer > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Advanced Non-Small Cell Lung Cancer Survival With Gefitinib Comparable to First Line Chemotherapy: Presented at ERS

        By Crystal Phend

        GLASGOW, SCOTLAND -- September 7, 2004 -- Gefitinib's potential to extend survival in patients with advanced non-small cell lung cancer (NSCLC) has been confirmed in a study with "very robust" results, said researchers here at the European Respiratory Society 14th Annual Congress.

        "This is 'real world' data showing 1-year survival of about 30%, which is comparable to that of single agent chemotherapy in the recurrent setting," said Mikael von Euler, MD, PhD, AstraZeneca, Alderley Park, Macclesfield, United Kingdom.

        Previously, all data on survival rates for patients treated with gefitinib (Iressa TM, zd1839) was based on clinical trials with typically about 200 patients, said Dr. Euler, who presented the results here September 6th.

        The compassionate use program, the largest ever in the United States, followed 9,501 patients for a minimum of 1 year and treated 21,064 patients with at least 1 dose. Patients were in stage III or IV of the disease and had failed or were intolerant to chemotherapy.

        Treatment in the non-randomised, open-label program was measured from therapy start to the patient's last re-supply for ongoing patients or to last dose for those who withdrew. Patients received 250 mg daily. Notably, 23.1% of patients were older than 75 years and 71.8% were in stage IV of the disease.

        The 1-year survival rate for these advanced non-small cell lung cancer patients was 29.9%, with a narrow 95% confidence interval of 28.8 to 31.1%.

        Third- or forth-line treatments for the disease typically have about a 5% 1-year survival rate whereas first- or second-line chemotherapy treatment yields a rate of about 35%, Dr. Euler said. Gefitinib thus represents a large improvement for patients who cannot tolerate chemotherapy or have a refractory condition, he said.

        "One-year survival was the same as you would expect in patients who have not been treated [previously with chemotherapy]," Dr. Euler said.

        Side effects were mild compared to those generally seen with chemotherapy, according to Dr. Euler. Drug related serious adverse events occurred in 2.3% of patients, 0.3% had a drug-related death, and 1.1% discontinued therapy. The incidence of interstitial lung disease from all causes was 0.3%; one third of cases were fatal.

        Gefitinib is an orally active compound that appears to prevent lung cancer cells from growing and multiplying. It is an epidermal growth factor receptor tyrosine kinase inhibitor used for patients with stage III or IV non-small cell lung cancer.


        [Presentation title: "Compassionate-Use Gefitinib in Non–Small Cell Lung Cancer (NSCLC): Results From a US Expanded Access Program (EAP)." Abstract 1524]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send